

Robert Greene Sterne Jorge A. Goldstein David K.S. Comwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee John M. Covert Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim Jeffrey T. Hebevy Eldora L. Ellison

Peter A. Jackman Brian J. Del Buono Mark Fox Evens Vincent L. Capuane Citzabeth J. Haanes Michael D. Specht Kevin W. McCabe Glenn J. Petry Edward W. Yee Grant E. Reed Virgil Lee Beaston Theodore A. Wood Joseph S. Ostroff Jason D. Eisenberg Tracy L. Muller Jon E. Wright LuAnne M. DeSantis Ann E. Summerfield Helene C. Carlson Cynthia M. Bouchez Timothy A. Doyle Gaby L. Longsworth Lori A. Gordon Laura A. Vogel Bryan S. Wade Bashir M.S. Ali Shannon A. Carroll Anbar F. Khal Michelle K. Holoubek Marsha A. Rose Scott A. Schaller Lei Zhou Young Tang Christopher J. Walsh W. Blake Coblentz* James J. Pohl John T. Haran Mark W. Rygiel

Michael R. Malek*
Carla Ji-Eun Kim
Doyle A. Siever*
Ulrike Winkler
Bryan L. Skelton*
Paul A. Calvo
Robert A. Schwartzman
C. Matthew Rozier
Alexandra K. Pechhold
Registered Patent Agent

Registered Patent Agents • Karen R. Markowicz Matthew J. Dowd Katrina Yujian Pei Quach Julie A. Heider Mita Mukherjee Scott M. Woodhouse Peter A. Socarras Jeffrey K. Mills Danielle L. Letting Lori Brandes Steven C. Oppenheimer Aaron S. Lukas Gaurav Asthana

Of Counsel Edward J. Kessler Kenneth C. Bass III Marvin C. Guthrie Christopher P. Wrist

*Admitted only in Maryland *Admitted only in Virginia •Practice Limited to Federal Agencies

June 25, 2007

WRITER'S DIRECT NUMBER: (202) 772-8851 INTERNET ADDRESS: RSCHWART@SKGF.COM

Mail Stop: Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 10/614,116; Filed: July 3, 2003

For: Ketone Ligands for Modulating the Expression of Exogenous Genes

Via an Ecdysone Receptor Complex

Inventors: TICE et al.

Our Ref: 2584.0020001/RWE/RAS

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
- 2. One (1) page of Form PTO/SB/08A citing ten (10) documents;
- 3. A copy of five (5) of the cited documents (FP1-FP5);
- 4. Three (3) pages of Form PTO/SB/08B citing twenty (20) documents; and
- 5. A copy of the twenty (20) cited documents (NPL1-NPL20).

The above-listed documents are filed electronically through EFS-Web.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents June 25, 2007 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert A. Schwartzman, Ph.D.

Attorney for Applicants Registration No. 50,211

RAS/las Enclosures 690848 1.DOC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Confirmation No.: 3335

TICE et al. Art Unit: 1633

Appl. No.: 10/614,116 Examiner: Popa, Ileana

Filed: July 3, 2003 Atty. Docket: 2584.0020001/RWE/RAS

For: **Ketone Ligands for Modulating** the Expression of Exogenous

Genes Via An Ecdysone Receptor

Complex

Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents **FP1** to **FP5** and **NPL1** to **NPL20** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents, **US1** to **US5**, cited on the attached IDS Form, PTO/SB/08A, are not submitted.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language documents, **FP1-FP4**, **NPL1** and **NPL15**, cited on Forms PTO/SB/08A and PTO/SB/08B:

FP1, WO 01/60783 A1, is in a foreign language. An English language abstract of document FP1 is provided on the face page of the document.

FP2, WO 02/051820 A1, is in a foreign language. An English language abstract of document FP2 is provided on the face page of the document.

- FP3, WO 02/053543 A1, is in a foreign language. An English language abstract of document FP3 is provided on the face page of the document.
- **FP4**, WO 02/059077 A1, is in a foreign language. An English language abstract of document FP4 is provided on the face page of the document.
- NPL1, Aumann, R., and Heinen, H., "(C-Amino)ketenimine, 2-Imidazolin-5-one and α-Aminosäureamide aus (Aminocarben)chromkomplexen und Isocyaniden," *Chem. Ber. 122*:1139-1145, VHC Verlagsgesellschaft mbH (1989), is in a foreign language. An English language abstract of document NPL1 is attached as document NPL19.
- **NPL15**, Sidel, W and Nahm, H, "Über die Hydrierug von α-Benzoyl-*N*-acylserin-benzylestern," *Chem. Ber.* 88:900-911 (1955), VHC Verlagsgesellschaft mbH (1955), is in a foreign language. An English language abstract of document NPL16 is attached as document **NPL20**.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. §1.114, filed herewith. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert A. Schwartzman, Ph.D.

Attorney for Applicants Registration No. 50,211

Date: June 25, 2007

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

684525v1

Equivalent of Form PTO/SB/08A (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute f	Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/614,116	
INFOR	MAT	ON E	DISCL	OSURE	Filing Date	July 3, 2003
STATE	MEN	T BY	APP	LICANT	First Named Inventor	TICE, Colin M.
			ets as ne		Art Unit	1633
			•	Examiner Name	Popa, Ileana	
Sheet	1	of	1	·	Attorney Docket Number	2584.0020001/RWE/RAS

			U.S. PATENT DO	CUMENTS		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
imilais		Number-Kind Code ^{2 (If Known)}	MM BB TTT	rippineum of Cited Boodmont	or Relevant Figures Appear	
	US1	3,676,453	07/11/1972	Pines et al.		
	US2	3,716,573	02/13/1973	Pives		
	US3	4,971,993	11/20/1990	Kurauchi et al.		
	US4	5,324,483	06/28/1994	Cody et al.		
	US5	5,523,308	06/04/1996	Costanzo et al.		
		-	 			
			1			
			 			
					 	

	r		REIGN PATENT DO		T	
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			Relevant Passages or Relevant Figures Appear	T ⁶
	FP1	WO 01/60783 A1	08/23/2001	Ishihara Sangyo Kaisha, Ltd.		Abs
	FP2	WO 02/051820 A1	07/04/2002	Ono Pharmaceutical Co., Ltd.		Abs
	FP3	WO 02/053543 A1	07/11/2002	Shionogi & Co., Ltd.		Abs
	FP4	WO 02/059077 A1	08/01/2002	Takeda Chemical Industries, Ltd.		Abs
	FP5	EP 0 405 537 B1	09/08/2004	Warner-Lambert Company LLC		
	11.5					

683468v1

Examiner	Date	
Signature	 Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Equivalent of Form PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Ca	mplete if Known			
			Application Number	10/614,116			
INFOR	MATION	I DISCLOSURE	Filing Date	July 3, 2003			
		BY APPLICANT	First Named Inventor	TICE, Colin M.			
0.,,		ny sheets as necessary)	Art Unit	1633			
			Examiner Name	Popa, Ileana	·		
Sheet	1	of 3	Attorney Docket Number				
	, ,	NON PATE	NT LITERATURE DOCUME				
Examiner Initials*	Cite No. ¹	Include name of the author of the item (book, magazine,	(in CAPITAL LETTERS), title of	the article (when appropriate), title og, etc.), date, page(s), volume-issue	T ²		
	NPL1	Aminosäureamide aus (n, H., "(C-Amino)ketenimi Aminocarben)chromkompl 145, VHC Verlagsgesellsch		Abs		
	NPL2		dies on 2-Phenyl-4-Arlyide 6, Pergamon Press Ltd. (19				
	NPL3	Inhibitors of Caspase-3	entification of Potent and S through the Use of Extende <i>Med. Chem. 45</i> :5005-5022				
	Él'kinson R.S. and Eremeev, A.V., "Reactions of Azirines with Sulfur Nucleophiles. 4. Treatment of 2H-Azirine With Mercaptosubstituted Acids. NPL4 Reactions of Aziridinyl Alkyl Sulfides With Carboxylic Acids and Acyl Chloride Derivatives," <i>Chem. Heterocycl. Compd.</i> 22:161-166, Plenum Publishing Corporation (1986)			ercaptosubstituted Acids. xylic Acids and Acyl			
	NPL5	application to the synth	man, M., "Concise route to esis of a simplified azinomy 73-9576, Elsevier Science				
	NPL6		Huebner, C.F., and Scholz, C.R., "The Synthesis of Cholramphenical Analogs," J. Am. Chem. Soc 73:2089-2094, American Chemical Society (1951)				
NPL7		Lachicotte, R.J., et al., "C-Acylation of Hippurate and Related Esters Utilizing Multiple Anion Intermediate and Ethyl 4-Aminobenzoate," Synth. Commun. 20:63-69, Marcel Dekker, Inc. (1990)					
	NPL8 amino-Weinreb amides u		d syntheses of α-BOC-amin using a pre-deprotonation p Science Ltd. (Nov 2002)	oketones from α-BOC- protocol," <i>Tetrahedron Lett</i> .			
MacPherson, E.J. and Smi		mith J.G., "Alkali metal adducts of benzophenone azine. sium adducts," <i>Can. J. Chem.</i> 48:1904-1914, NRC					

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Equivalent of Form PTO/SB/08B (04-07) Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO				Com	Complete if Known		
				Application Number	10/614,116		
INFORM	INFORMATION DISCLOSURE			Filing Date	July 3, 2003		
STATEM	STATEMENT BY APPLICANT			First Named Inventor	TICE, Colin M.		
	(Use as many			Art Unit	1633		
·				Examiner Name	Popa, Ileana		
Sheet	2	of	3	Attorney Docket Number	2584.0020001/RWE/RAS		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL10	Mizuno, H., et al., "Stereochemical Studies. V11: Thermal Rearrangement of α-Hydroxyimines to α-Aminoketones using optically Active Open Chain Compounds," <i>Chem. Pharm. Bull.</i> 71:227-246, Pharmaceutical Society of Japan (1971)	
	NPL11	Ooi, T., et al., "Asymmetric Induction in the Neber Rearrangement of Simple Ketoxime Sulfonates under Phase-Transfer Conditions: Experimental Evidence for the Participation of an Anionic Pathway," J. Am. Chem. Soc. 124:7640-7641, American Chemical Society (June 2002)	
	NPL12	Pines, H.S., et al., "3-Aryl-2-methylserines. I. A New Synthesis," J.Org. Chem. 33:1758-1761, American Chemical Society (1968)	
	NPL13	Pines, S.H., and Sletzinger, M., "3-Aryl-2-Methylserines III. Synthesis <u>via</u> Alanine Azlactone," <i>Tetrahedron Lett.</i> 9:727-728, Pergamon Press (1969)	
	NPL14	Pines, S.H., et al., "3-Aryl-2-methylserines. II. Inversions at Carbon 3," J. Org. Chem. 33:1762-1767, American Chemical Society (1968)	,
	NPL15	Siedel, W and Nahm, H, "Über die Hydrierung von α-Benzoyl-N-acyl-serinbenzylestern," <i>Chem. Ber.</i> 88:900-911, VHC Verlagsgesellschaft mbH (1955)	Ab
	NPL16	Subramanyam, C., and Chang, S.P., "Solid-Phase synthesis of peptidyl α-keto heterocycles," <i>Tetrahedron Lett.</i> 43:6313-6315, Elsevier Science Ltd. (Sept 2002)	
	NPL17	Tamaru, Y., et al., "Sulfinate As Cocatalyst 3: Palladium Catalyzed Dimerization of Butadiene with Acylamino Ketones," <i>Tetrahedron Lett.</i> 21:3791-3794, Pergamon Press Ltd. (1980)	
	NPL18	Van Der Meer, S., et al., "Chloramphenicol Analogues I DL-2- Dichloroacetamido-1-(4-pyridyl)-1,3-propanediol," <i>Recl. Trav. Chim. Pays-Bas</i> 72:236-246, Société chimique neerlandaise (1953)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Equivalent of Form PTO/SB/08B (04-07) Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/614,116	
INFOR	MATION	DISC	LOSURE	Filing Date	July 3, 2003	
1			PLICANT	First Named Inventor	TICE, Colin M.	
• –			s necessary)	Art Unit	1633	
	,		•	Examiner Name	Popa, Ileana	
Sheet	3	of	3	Attorney Docket Number	2584.0020001/RWE/RAS	
				LITERATURE DOCUMENT		
Examiner Initials*	Cite No. ¹		e item (book, magazine,	CAPITAL LETTERS), title of the journal, serial, symposium, cataloublisher, city and/or country wher	og, etc.), date, page(s), volume	T ²
	NPL19	STNEasy Database, Accession No.1989:422724, English language abstract for			2-Imidazolin-5-one and α-en und Isocyaniden," <i>Chem.</i>	
	NPL20	Sidel,	W and Nahm, H, "Ü	ssion No. 1956:40246, Eng Iber die Hydrierug von α-Be 88:900-911, VHC Verlags	enzoyl-N-acyl-serin-	
!						
683545v1						

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.